Gut bacterial enzyme keeps inflammation away
An antimicrobial molecule produced by the human microbiota gut may help fight drug-resistant infections.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Entries by Thomas Gabrielczyk
Tacalyx GmbH raises 7m in seed funding
/in News/by Thomas GabrielczykGerman Tacalyx GmbH has baged 7m in seed financing to generate antibodies that home in on tumour-antigene specific carbohydrates (TACAs) of glycans.
EMA greenlights new medicines
/in News/by Thomas GabrielczykAt its September meeting, the EMAs CHMP recommended three innovative medicines for EU market approval.
New malaria lead kills 99.9% of pathogens
/in News/by Thomas GabrielczykDutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Versantis raises CHF16m in Series B financing
/in News/by Thomas GabrielczykSwiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Lundback swallows migraine drug maker Alder
/in News/by Thomas GabrielczykDanish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (1.76bn) to acquire Alder BioPharmaceuticals Inc.
PFF Group NV acquires stake in Autolus Therapeutics
/in News/by Thomas GabrielczykPrague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
Researchers identify CTLA-4 response marker
/in News/by Thomas GabrielczykGerman and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
Inotrem SA raises 39m to provide POC for nangibotide
/in News/by Thomas GabrielczykFrench biotech Inotrem SA raised 39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.